{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:52Z","timestamp":1747181212333,"version":"3.40.5"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:p>Peripheral T-cell lymphoma is a disease that includes multiple T-cell lymphoma subtypes. It is still unclear whether CD30 can be used as a new target molecule and classification standard for PTCL. Differences in the molecular characteristics of CD30-positive PTCL and CD30-negative PTCL have rarely been reported. This study aimed to analyze the expression of BCL11b and CDKN2A in CD30-positive PTCL and CD30-negative PTCL, in order to guide the pathological classification, prognosis, and clinical treatment of PTCL. Immunohistochemical staining and quantitative reverse-transcription PCR (qRT-PCR) were performed on formalin-fixed paraffin-embedded tissue. Verification of BCL11b and CDKN2A expression in ALCL, PTCL-NOS, AITL and NK\/TCL. Based on immunohistochemical analysis, the expression level of BCL11b in the lymph node reactive hyperplasia control group was high at 85.0%, which was higher than 68.8% in CD30-positive PTCL and 44.1% in CD30-negative PTCL (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05, respectively). CDKN2A showed expression rates of 70.0% in the control group, 79.2% in CD30-positive PTCL and 79.4% in CD30-negative PTCL. qRT-PCR showed that the relative BCL11b mRNA expression levels in patients with PTCL were lower than those in the control group (0.694 vs 1.832, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.045). Univariate analysis showed that international prognostic index score, CD30 expression, and BCL11b expression were closely related to prognosis (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05, respectively). Multivariate Cox regression analysis revealed that high expression of BCL11b mRNA was an independent factor affecting prognosis (respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Spearman correlation analysis indicated that BCL11b expression had a significant positive correlation with CD30 expression (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.005). These results indicate that BCL11b may be involved in CD30 differentiation and PTCL prognosis. The detection and targeting of BCL11b and CD30 may provide new strategies for the treatment and classification of PTCL.<\/jats:p>","DOI":"10.1097\/md.0000000000035531","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T09:27:05Z","timestamp":1701163625000},"page":"e35531","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-8616","authenticated-orcid":false,"given":"Yajing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology, Shanxi Province Cancer Hospital\/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanxi Province Cancer Hospital\/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanxi Province Cancer Hospital\/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanxi Province Cancer Hospital\/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanxi Province Cancer Hospital\/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanxi Province Cancer Hospital\/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People\u2019s Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project.","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.beha.2018.07.010","article-title":"Peripheral T-cell lymphoma - are we making progress?","volume":"31","author":"Khan","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma.","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.hoc.2019.04.002","article-title":"Peripheral T-Cell lymphoma: moving toward targeted therapies.","volume":"33","author":"Ng","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543784.2011.641532","article-title":"Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.","volume":"21","author":"Gualberto","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.","volume":"10","author":"Pierce","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1084\/jem.20171127","article-title":"Bcl11b, a novel GATA3-interacting protein, suppresses Th1 while limiting Th2 cell differentiation.","volume":"215","author":"Fang","year":"2018","journal-title":"J Exp Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2183\/pjab.88.72","article-title":"Role of the transcription factor Bcl11b in development and lymphomagenesis.","volume":"88","author":"Kominami","year":"2012","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5301\/tj.5000524","article-title":"Management of HPV-related cervical disease: role of p16INK4a immunochemistry review of the literature.","volume":"102","author":"Savone","year":"2016","journal-title":"Tumori"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia.","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/cancers12030644","article-title":"High specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG positive Ewing Sarcoma.","volume":"12","author":"Orth","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.28727","article-title":"Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.","volume":"135","author":"Lim","year":"2014","journal-title":"Int J Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2020.262659","article-title":"<i>CDKN2A<\/i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).","volume":"106","author":"Maura","year":"2021","journal-title":"Haematologica"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/leu.2017.70","article-title":"The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.","volume":"31","author":"Ha","year":"2017","journal-title":"Leukemia"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4049\/jimmunol.163.1.194","article-title":"CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway.","volume":"163","author":"Chiarle","year":"1999","journal-title":"J Immunol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.cellsig.2011.12.026","article-title":"BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner.","volume":"24","author":"Obata","year":"2012","journal-title":"Cell Signal"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T08:03:02Z","timestamp":1746345782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":20,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035531","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}